Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Jun. 2026, Dolphin Medical Services has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Dolphin Medical Services (BOM:526504) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, Dolphin Medical Services has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Dolphin Medical Services Sloan Ratio % Related Terms
Dolphin Medical Services Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526504 vs TMO, DHR, NTRA: Sloan Ratio % Comparison
For the Diagnostics & Research subindustry, Dolphin Medical Services's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dolphin Medical Services Sloan Ratio % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dolphin Medical Services's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Dolphin Medical Services's Sloan Ratio % falls into.
Dolphin Medical Services Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Dolphin Medical Services's Sloan Ratio for the fiscal year that ended in Mar. 2026 is calculated as
Dolphin Medical Services's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was 0.06 (Sep. 2025 ) + 0.168 (Dec. 2025 ) + 0.071 (Mar. 2026 ) + 0.178 (Jun. 2026 ) = ₹0.48 Mil.
Dolphin Medical Services's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 0 (Sep. 2025 ) + 0 (Dec. 2025 ) + 0 (Mar. 2026 ) + 0 (Jun. 2026 ) = ₹0.00 Mil.
Dolphin Medical Services's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was 0 (Sep. 2025 ) + 0 (Dec. 2025 ) + 0 (Mar. 2026 ) + 0 (Jun. 2026 ) = ₹0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dolphin Medical Services (BOM:526504) has a Sloan Ratio % of 0.00% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Dolphin Medical Services and its competitors.
Is Dolphin Medical Services' Sloan Ratio % too high?
Dolphin Medical Services' current Sloan Ratio % is 0.00%. Overall, Dolphin Medical Services has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dolphin Medical Services' Sloan Ratio % compare to TMO and DHR?
Dolphin Medical Services' Sloan Ratio % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Diagnostics & Research company?
A good Sloan Ratio % depends on the Medical Diagnostics & Research industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Dolphin Medical Services and its competitors. Dolphin Medical Services's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dolphin Medical Services stock overvalued right now?
Based on GuruFocus' analysis, Dolphin Medical Services (BOM:526504) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹2.59, compared to a current price of ₹6.64 — trading 156.4% above its estimated fair value. The current Sloan Ratio % is 0.00%. Dolphin Medical Services' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Dolphin Medical Services (BOM:526504), the current Sloan Ratio % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dolphin Medical Services (BOM:526504) Overvalued in 2026?
Based on GuruFocus' analysis, Dolphin Medical Services stock appears to be overvalued.
The current stock price of ₹6.64 is trading 156.4% above its estimated GF Value™ of ₹2.59.
GuruFocus considers Dolphin Medical Services to be Significantly Overvalued.
Key valuation signals for BOM:526504:
Sloan Ratio %: 0.00%
GF Value™: ₹2.59 vs. price of ₹6.64 (156.4% above fair value)
No single metric tells the full story. See the BOM:526504 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dolphin Medical Services Ltd is engaged in providing diagnostics and other allied services. It includes a range of tests covering radiology and imaging, biochemistry, pathology, and microbiology. In addition, the company is also involved in Information Technology, Biotechnology, and Herbal sectors. Services provided by the company are Diagnostic Centre provides all the services under one roof; the Ophthalmic Laser Care Centre provides total laser eye treatment as "Dolphin Nethralaya"; Teleradiology Services; Clinical Trials and Life Sciences division; Medical Equipment & Goods associated distribution; Bio-Tech Division is to provide Foods and Herbal Products and Dolphin Electronic Solution and Technologies(DEST).
37GF Score
Get the complete analysis for BOM:526504
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526504 has been successfully added to your 
